Journal
RHEUMATOLOGY
Volume 60, Issue -, Pages II45-II51Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/keaa896
Keywords
inflammatory bowel disease; ulcerative colitis; Crohn's disease; JAK1 inhibitors
Categories
Funding
- Gilead
Ask authors/readers for more resources
Primary non-response and secondary loss of response are still significant issues with current treatment options for inflammatory bowel disease, highlighting the need for new therapeutic choices. As our understanding of IBD pathogenesis advances, new therapeutic targets are being identified.
Primary non-response and secondary loss of response remain a significant issue with the currently available treatment options for a significant proportion of patients with inflammatory bowel disease (IBD). There are multiple unmet needs in the IBD treatment algorithm and new treatment options are required. As our understanding of the pathogenesis of IBD evolves, new therapeutic targets are being identified. The JAK-STAT pathway has been extensively studied. Tofacitinib, a JAK1 inhibitor, is now licensed for use in the induction and maintenance of ulcerative colitis and there are a large number of molecules currently under investigation. These new small molecule drugs (SMDs) will challenge current treatment pathways at a time when clinical therapeutic outcomes are rapidly evolving and becoming more ambitious. This is a review of the current JAK1 inhibitors in IBD including the current evidence from clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available